Satsuma Pharmaceuticals
About Satsuma Pharmaceuticals
Satsuma Pharmaceuticals is a company based in San Francisco (United States) founded in 2016 was acquired by Shin Nippon Biomedical Laboratories in April 2023.. Satsuma Pharmaceuticals has raised $74.13 million across 2 funding rounds from investors including TPG, RA Capital and Surveyor Health. The company has 24 employees as of December 31, 2022. Satsuma Pharmaceuticals offers products and services including STS101 and Dihydroergotamine. Satsuma Pharmaceuticals operates in a competitive market with competitors including Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others.
- Headquarter San Francisco, United States
- Employees 24 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Satsuma Pharmaceuticals, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$74.13 M (USD)
in 2 rounds
-
Latest Funding Round
$62 M (USD), Series B
Apr 24, 2019
-
Investors
TPG
& 11 more
-
Employee Count
24
as on Dec 31, 2022
-
Acquired by
Shin Nippon Biomedical Laboratories
(Apr 16, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Satsuma Pharmaceuticals
Satsuma Pharmaceuticals offers a comprehensive portfolio of products and services, including STS101 and Dihydroergotamine. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Nasal powder for acute migraine treatment with or without aura.
Active ingredient in therapeutics for fast migraine relief.
Unlock access to complete
Funding Insights of Satsuma Pharmaceuticals
Satsuma Pharmaceuticals has successfully raised a total of $74.13M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $62 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $62.0M
-
First Round
First Round
(05 Jan 2017)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2019 | Amount | Series B - Satsuma Pharmaceuticals | Valuation | Wellington | |
| Jan, 2017 | Amount | Series A - Satsuma Pharmaceuticals | Valuation | RA Capital Management , TPG |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Satsuma Pharmaceuticals
Satsuma Pharmaceuticals has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include TPG, RA Capital and Surveyor Health. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Fund of funds focused on pre-seed and seed-stage companies
|
Founded Year | Domain | Location | |
|
Early- to growth-stage startups are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Lumira Ventures is engaged in life sciences venture capital investment.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Satsuma Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Satsuma Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Satsuma Pharmaceuticals Comparisons
Competitors of Satsuma Pharmaceuticals
Satsuma Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| domain | founded_year | HQ Location |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| domain | founded_year | HQ Location |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| domain | founded_year | HQ Location |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for pain and addiction treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for pain management are developed with abuse-deterrent designs.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Satsuma Pharmaceuticals
Frequently Asked Questions about Satsuma Pharmaceuticals
When was Satsuma Pharmaceuticals founded?
Satsuma Pharmaceuticals was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Satsuma Pharmaceuticals located?
Satsuma Pharmaceuticals is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Satsuma Pharmaceuticals a funded company?
Satsuma Pharmaceuticals is a funded company, having raised a total of $74.13M across 2 funding rounds to date. The company's 1st funding round was a Series A of $12.13M, raised on Jan 05, 2017.
How many employees does Satsuma Pharmaceuticals have?
As of Dec 31, 2022, the latest employee count at Satsuma Pharmaceuticals is 24.
What does Satsuma Pharmaceuticals do?
Satsuma Pharmaceuticals was founded in 2016 in San Francisco, United States, within the pharmaceuticals sector. Therapeutics targeted at migraine sufferers are developed by the company. Operations center on the lead product STS101, which is formulated as a proprietary nasal powder containing dihydroergotamine mesylate (DHE) for acute migraine treatment. This product is administered through a specialized nasal delivery device, with activities based in the U.S. healthcare domain.
Who are the top competitors of Satsuma Pharmaceuticals?
Satsuma Pharmaceuticals's top competitors include Flexion Therapeutics, Cara Therapeutics and PainReform.
What products or services does Satsuma Pharmaceuticals offer?
Satsuma Pharmaceuticals offers STS101 and Dihydroergotamine.
Who are Satsuma Pharmaceuticals's investors?
Satsuma Pharmaceuticals has 12 investors. Key investors include TPG, RA Capital, Surveyor Health, Wellington, and SNBL.